# US 2002/0055522 A1 · Meta-benzamidine derivatives as serine protease inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0055522 A1
- Document ID: US20020055522A1
- Status: Published application
- Kind: A1
- Application number: 09/988,082
- Filed: 2001-11-19
- Published: 2002-05-09
- Earliest claimed: 1997-08-29
- Assignees: Tularik Inc.
- Inventors: John Walter Liebeschuetz; William Alexander Wylie; Bohdan Waszkowycz; Christopher William Murray; Andrew David Rimmer; Pauline Mary Welsh; Stuart Donald Jones; Jonathan Michael Ernest Roscoe; Stephen Clinton Young; Phillip John Morgan
- Web page: https://patentgrep.com/patent/US20020055522A1

## CPC

- C07K 5/0207: {containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids}
- C07C 237/36: having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C 255/60: at least one of the singly-bound nitrogen atoms being acylated
- C07D 209/08: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C07D 209/30: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D 209/34: in position 2
- C07D 209/42: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 211/26: with hydrocarbon radicals, substituted by nitrogen atoms
- C07D 211/34: with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 211/46: having a hydrogen atom as the second substituent in position 4
- C07D 211/60: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 213/53: Nitrogen atoms
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 213/82: in position 3
- C07D 215/38: Nitrogen atoms (nitro radicals C07D215/18)
- C07D 217/04: with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C07D 217/06: with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
- C07D 217/22: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D 217/24: Oxygen atoms
- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- C07D 235/06: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D 241/24: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 277/28: Radicals substituted by nitrogen atoms
- C07D 277/46: by carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D 277/64: with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D 277/82: Nitrogen atoms
- C07D 295/135: with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 295/185: from aliphatic carboxylic acids
- C07D 317/68: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 333/38: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 333/68: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 401/14: containing three or more hetero rings
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 487/04: Ortho-condensed systems
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07C 2601/14: The ring being saturated
- C07C 2602/08: the other ring being five-membered, e.g. indane
- C07C 2602/10: the other ring being six-membered, e.g. tetraline
- C07C 2602/42: the bicyclo ring system containing seven carbon atoms
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compounds of formula I 1 in which R1, R2, R3, each X, L, Y, Cy, Lp, D and n have the meanings as set out in the specification, and corresponding compounds in which the unsubstituted or substituted amidine group is replaced with an unsubstituted or substituted aminomethyl group, are useful as serine protease inhibitors.

## Claims

### Claim 1

A serine protease inhibitor compound of formula (I)
81
or a corresponding compound in which the unsubstituted or substituted amidino group
82
is replaced with an unsubstituted or substituted aminomethyl group;
where R1 and R2 each independently is hydrogen or hydroxyl, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, acyloxymethoxycarbonyl or alkylamino optionally substitituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl;
each R3 independently is R1, R2, amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, alkylsulphonamido, alkylaminosulphonyl, haloalkoxy and haloalkyl;
each X independently is a C, N, O or S atom or a CO, CR1, C(R1)2 or NR1 group, at least one X being C, CO, CR1 or C(R1)2, with the proviso that if the benzamidine group is unsubstituted and the X—X group is —CH2C(R1)2— then R1 is hydrogen or is attached to the alkylene carbon atom by a heteroatom;
L is an organic linker group containing 1 to 5 backbone atoms selected from C, N, O and S, or a branched alkyl or cyclic group;
Y is a nitrogen atom or a CR1 group or Y and L taken together form a cyclic group;
Cy is a saturated or unsaturated, mono or poly cyclic, homo or heterocyclic group optionally substituted by groups R3 or phenyl optionally substituted by R3;
Lp is a lipophilic organic group, selected from an alkyl, heterocyclic, alkenyl, alkaryl, cycloalkyl, polycycloalkyl, cycloalkenyl, aryl, aralkyl or haloalkyl group or a combination of two or more such groups optionally substituted by one or more of oxa, oxo, aza, thio, halo, amino, hydroxy or R3 groups;
D is a hydrogen bond donor group; and
n is 0, 1 or 2;
or a physiologically tolerable salt thereof.

### Claim 2 (depends on 1)

A compound as claimed in claim 1 wherein R1 represents hydrogen.

### Claim 3 (depends on 1)

A compound as claimed in claim 1, wherein R2 is hydrogen, alkoxycarbonyl or hydroxy.

### Claim 4 (depends on 1)

A compound as claimed in claim 1 wherein R3 is hydrogen, amino, aminoalkyl, alkylamino, hydroxy, hydroxyalkyl, thiol, alkylthio or alkoxy.

### Claim 5 (depends on 4)

A compound as claimed in claim 4 wherein R3 is para to the amidino group.

### Claim 6 (depends on 5)

A compound as claimed in claim 5 wherein R3 is amino.

### Claim 7 (depends on 1)

A compound as claimed in claim 1 wherein the linker X—X is —CH═CH—, —CONH—, —CONR1—, —NH—CO—, —NH—CH2—, —CH2—NH—, —CH2O—, —OCH2—, —COO—, —OC═O— or —CH2CH2—.

### Claim 8 (depends on 7)

A compound as claimed in claim 7 wherein the X moiety nearest Y is NH.

### Claim 9 (depends on 7)

A compound as claimed in claim 7 wherein the X moiety nearest the phenyl ring is CH2 or CO.

### Claim 10 (depends on 7)

A compound as claimed in claim 7 wherein X—X is —CONH—.

### Claim 11 (depends on 1)

A compound as claimed in claim 1 wherein Y is CH.

### Claim 12 (depends on 1)

A compound as claimed in claim 1 wherein Cy represents aryl or heteroaryl optionally substituted by R3.

### Claim 13 (depends on 12)

A compound as claimed in claim 12 wherein Cy represents phenyl optionally substituted by R3 or naphthyl optionally substituted by R3.

### Claim 14 (depends on 13)

A compound as claimed in claim 13 wherein Cy represents phenyl.

### Claim 15 (depends on 1)

A compound as claimed in claim 1 wherein the linker L represents CO, CH2NH, CONR1(CH2)m, (CH2)mN(R1)CO(CH2)m, (CH2)m+2, (CH2)mCO(CH2)m, (CH2)mOC═O, (CH2)m or CH═CH (CH2)m (where each m is independently 0 or 1).

### Claim 16 (depends on 15)

A compound as claimed in claim 15 wherein the linker L represents CONR1(CH2)m, CO or CH2NR1CO where m is 0 or 1.

### Claim 17 (depends on 1)

A compound as claimed in claim 1 wherein said lipophilic group comprises cycloalkyl, azacycloalkyl, diazacycloalkyl, phenyl, naphthyl, adamantyl, decalinyl, tetrahydrodecalinyl, bicycloalkyl, mono- or diazabicycloalkyl, mono-, bicyclo heteroaromatic or a linear or branched alkyl, alkylene, alkenyl or alkenylene group all optionally substituted by one or more groups R3, or a combination of at least two such groups linked by a Spiro linkage or a single or double bond or by C═O, O, S, SO, SO2, CONR1, NR1—CO—, NR1 linkage.

### Claim 18 (depends on 17)

A compound as claimed in claim 17 wherein the lipophilic group is a methylcyclohexyl, methylcyclohexylmethyl, methylphenylmethyl, phenylethyl, benzylpiperidinyl, benzoylpiperidinyl, bispiperidinyl or phenylpiperazinyl.

### Claim 19 (depends on 1)

A compound as claimed in claim 1 wherein the hydrogen bond donor group is attached to the lipophilic group.

### Claim 20 (depends on 19)

A compound as claimed in claim 19 wherein nitrogen or oxygen is the hydrogen bond donor atom.

### Claim 21 (depends on 20)

A compound as claimed in claim 20 wherein the hydrogen bond donor is formed from a hydroxyl group, a primary, secondary or tertiary amine, or a primary or secondary imine group as part of an amidine or guanidine or a saturated or unsaturated heterocyclic group containing 5 to 7 ring atoms and having a ring nitrogen.

### Claim 22 (depends on 1)

A compound as claimed in claim 1 wherein Y is carbon and has the conformation that would result from construction from a D-α-aminoacid NH2—CR1(Cy)—COOH.

### Claim 23 (depends on 1)

A compound as claimed in claim 1 being 3-amidinobenzoyl-D-phenylglycine-4-benzoyl piperidinamide.

### Claim 24 (depends on 1)

A pharmaceutical composition comprising a serine protease inhibitor as claimed in claim 1 together with at least one pharmaceutically acceptable carrier or excipient.

### Claim 25 (depends on 1)

A method of treatment of the human or non-human animal body to combat a condition responsive to a serine protease inhibitor, said method comprising administering to said body an effective amount of a serine protease inhibitor as claimed in claim 1.

### Claim 26 (depends on 25)

A method as claimed in claim 25, wherein said condition is a thrombotic disease, asthma, emphysema, cirrhosis, arthritis, carcinoma, melanoma, restenois, atheroma, trauma, shock or reperfusion injury.

### Claim 27

A serine protease inhibitor compound of formula (I)
83
or a corresponding compound in which the unsubstituted or substituted amidino group
84
is replaced with an unsubstituted or substituted aminomethylgroup;
where R1 represents hydrogen;
R2 represents hydrogen, alkoxycarbonyl or hydroxy;
R3 is hydrogen, amino, aminoalkyl, alkylamino, hydroxy, hydroxyalkyl, thiol, alkylthio or alkoxy;
X—X is CONH;
L is CO, CH2NH, CONR1(CH2)m, (CH2)mN(R1)CO(CH2)m, (CH2)m+2, (CH2)mCO(CH2)m, (CH2)mOC═O, (CH2)mO or CH═CH(CH2)m (where each m is independently 0 or 1).
Y is CH;
Cy represents phenyl optionally substituted by R3 or naphthyl optionally substituted by R3;
Lp is a lipophilic organic group, selected from an alkyl, heterocyclic, alkenyl, alkaryl, cycloalkyl, polycycloalkyl, cycloalkenyl, aryl, aralkyl or haloalkyl group or a combination of two or more such groups optionally substituted by one or more of oxa, oxo, aza, thio, halo, amino, hydroxy or R3 groups;
D is a hydrogen bond donor group; and n is 0, 1 or 2;
or a physiologically tolerable salt thereof.

### Claim 28 (depends on 27)

A compound as claimed in claim 27, in which the group
85
represents an unsubstituted amidine group, or a corresponding compound in which said group is replaced with an unsubstituted aminomethyl group.

### Claim 29 (depends on 27)

A pharmaceutical composition comprising a serine protease inhibitor as claimed in claim 27 together with at least one pharmaceutically acceptable carrier or excipent.

### Claim 30 (depends on 27)

A method of treatment of the human or non-human animal body to combat a condition responsive to a serine protease inhibitor, said method comprising administering to said body an effective amount of a serine protease inhibitor as claimed in claim 27.
